We are developing a biomarker-guided precision medicine to reduce barrier damage that manifests as Sepsis, COVID-19 and other acute host responses to bacterial, viral or fungal pathogen infection. Inthelia’s non-antimicrobial approach aims to save lives and improve health of patients where there are limited or no treatment options while also mitigating against the risk of antimicrobial resistance.
New Website Coming Soon
Precision Guided Medicine
To harness the power of cutting-edge science and innovative technologies to develop and deliver transformative precision therapies to treat infectious disease.